drugset / Trial / NCT02546310

Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects

NCT02546310 ↗

Phase 1 Completed 54 enrolled Nxera Pharma UK Limited P1vital Limited · collab
RandomizedParallel-groupTriple-blindBasic science

Summary

To determine if treatment with HTL0009936 will lead to changes in neural activity, measured using the fMRI BOLD signal and ASL, in brain areas that are associated with spatial and working memory, learning and executive functioning.

Timeline

Start
2015-10
Primary completion
2017-02
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Subject HTL-9936 Small molecule — —

Indications